Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
  • Pharmaceutical
    • INM-901 for Alzheimer’s Disease
    • INM-089 for Age-related Macular Degeneration
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Analogs
  • Manufacturing
    • BayMedica – Rare Cannabinoid Ingredients
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
    • Investor Contact
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisors
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
Small Molecule Therapeutics Targeting CB1/CB2
InMed’s pipeline consists of three programs in the treatment of Alzheimer’s disease, ocular and dermatological indications.
Learn More

Pipeline of small molecule therapeutics

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. 

Targeting CB1 and CB2 pathways

InMed has initiated three pharmaceutical programs – including preclinical programs in Alzheimer’s disease and age-related macular degeneration, as well as a completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.

InMed’s small molecule compounds are demonstrating promising effects with potentially multiple mechanisms.

Learn about our programs
InMed INM-901 MOA Alzheimer's Pathology

INM-901 demonstrates a multi-factorial approach to treating Alzheimer’s disease

INM-901 demonstrates multiple pharmacological effects in preclinical studies including neuroprotective effects, an ability to extend the length of neurites which is important for brain cell-to-cell communication, as well as a reduction in neuroinflammation. These preclinical studies were conducted in well-characterized study models of Alzheimer’s disease.

Learn about INM-901 Alzheimer's Studies

A library of analogs that can be selectively modified

Unlike natural cannabinoids isolated from the plant which are not patentable, our proprietary cannabinoid analogs are patentable and are recognized as new chemical entities (NCEs). These analogs are expected to offer similar or improved therapeutic effects compared to their parent (naturally occurring) cannabinoid with modifications that may make them preferred candidates to treat specific diseases. We are screening these analogs for their therapeutic properties and pharmaceutical development.

Learn About Our Cannabinoid Analogs
Baymedica logo color 2023 square

Bringing you highly pure, premium bioidentical rare cannabinoids

InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBTC) which are available for B2B purchase.

Learn about our BAYMEDICA'S PRODUCTS

Experienced team with a successful track record

Together, InMed and BayMedica bring extensive know-how in pharmaceutical research and development and manufacturing. We’ve combined our complementary expertise to become a leading pharmaceutical R&D company and manufacturer of small molecule therapeutics targeting CB1/CB2 receptors.

Meet the team

Latest News

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

June 13, 2025
Read More »

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025
Read More »

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

February 12, 2025
Read More »

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

February 3, 2025
Read More »

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

January 22, 2025
Read More »

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

January 21, 2025
Read More »

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

June 13, 2025
Learn More

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025
Learn More

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

February 12, 2025
Learn More

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

February 3, 2025
Learn More

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

January 22, 2025
Learn More

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

January 21, 2025
Learn More
See all news

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP


INM-755

A cannabinol (CBN) topical cream which has completed a Phase 2 clinical trial for epidermolysis bullosa
Learn More

INM-901 for Alzheimer's Disease

INM-901 demonstrates unique therapeutic effects from current treatments
Learn More

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More
InMed-logo-mono

#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8

Pharmaceutical

  • INM-901 for Alzheimer’s Disease
  • INM-089 for Age-related Macular Degeneration
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Analogs

MANUFACTURING

  • BayMedica – Rare Cannabinoid Ingredients
  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM Materials
  • Filings
  • Presentations
  • Media & Videos
  • Investor Contact

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisors
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2025 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent*